Saturday 17 October 2026 Export GNTA’s income statement to Excel — free account

Genenta Science S.p.A. Unsponsored ADR

0.68 0.01 +1.49%

Follow GNTA

Alert me

Market cap: $32.3M
P/E: —
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 40.64%

Capital & Financial Ratios $m

Market Cap 32.28

Revenue —

Net Income (25.72)

Free Cash Flow (23.02)

Net Debt (23.25)

Current Ratio 14.16

Debt/Equity 0.35

P/E ratio —

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 10.95%

Next Y EPS Growth (15.22%)

Next Y revenue growth —

Next 5Y EPS Growth 28.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 76.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	31	20	14	32
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	33	23	16	34

	2022	2023	2024	2025
Payables	1	1	1	2
ST’ Debt	—	—	—	—
Other	0	0	0	0
	2	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	7.38%	(9.01%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(8)
’24	—	—	—	—	(7)
’23	—	—	—	—	(12)
’22	—	—	—	—	(8)
’21	—	—	—	—	(8)
’20	—	—	—	—	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(6)	—	(8)	(8)
’24	—	(2)	—	(7)	(7)
’23	—	(8)	—	(12)	(12)
’22	—	(3)	—	(8)	(8)
’21	—	(6)	—	(8)	(8)
’20	—	—	—	(7)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.37)
’24	—	—	—	—	(0.53)
’23	—	—	—	—	(0.69)
’22	—	—	—	—	(0.50)
’21	—	—	—	—	(0.43)
’20	—	—	—	—	(0.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	10.00	3.90	4.29	2.20	1.28	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	13.13	11.80	7.08	7.28	10.00
People
People	Employees	—	—	—	—	4	7	9	14	13	9
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(5)	(6)	(7)	(9)	(13)	(10)	(7)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(5)	(6)	(7)	(9)	(13)	(10)	(7)
	Depreciation	—	—	—	—	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.28)	(0.44)	(0.43)	(0.50)	(0.69)	(0.53)	(0.37)
	Cash flow	—	—	—	(0.15)	(0.47)	(0.55)	(0.43)	(0.67)	(0.37)	(0.39)
	Capex	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	(0.15)	(0.48)	(0.55)	(0.43)	(0.67)	(0.37)	(0.39)
	Book value	—	—	—	1.17	1.19	3.05	1.80	1.21	0.74	1.25
	Shares, m	—	—	—	18	15	15	18	18	18	20
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(3)	(7)	(8)	(8)	(12)	(7)	(8)
	Capex	—	—	—	—	0	0	0	0	0	0
	Free cash flow	—	—	—	(3)	(7)	(8)	(8)	(12)	(7)	(8)
Balance, $m
Balance, $m	Working capital	—	—	—	20	16	45	31	21	13	32
	Total debt	—	—	—	—	—	—	—	—	—	9
	Net debt	—	—	—	(23)	(18)	(44)	(31)	(20)	(14)	(23)
	Shareholders’ equity	—	—	—	21	17	46	33	22	14	25
Returns, %
Returns, %	ROA	—	—	—	(42.95)	(29.06)	(19.43)	(21.63)	(42.43)	(47.95)	(28.35)
	ROIC	—	—	—	0.00	0.00	(219.27)	(513.85)	(442.67)	0.00	(318.86)
	ROE	—	—	—	(25.93)	(33.21)	(20.67)	(22.68)	(45.90)	(54.13)	(38.65)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—
MGX Metagenomi Therapeutics, Inc.	$31.9M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
GRDX GridAI Technologies Corp.	$31.8M	— (loss-making)	—	—	n/m	−2,640.98% (below 0%: shrinking)	(42.49%)	(15,258.21%)	Compare
NXTC NextCure, Inc.	$31.5M	— (loss-making)	— (loss-making)	+1,549.08% (above 0%: growing)	n/m	+57.23% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$33.0M	—	—	+1,549.08%	—	−5.55%	50.00%	0.00%

All 614 Biotechnology stocks →

Genenta Science S.p.A. Unsponsored ADR (GNTA) key facts

Concern: Genenta Science S.p.A. Unsponsored ADR reported a net loss of $7.4 million, or a loss of $0.37 per share, for fiscal 2025.
Genenta Science S.p.A. Unsponsored ADR (GNTA) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, GNTA traded at $0.68, a market capitalization of $32.3 million.
Return on equity was −38.7% and debt-to-equity 0.35.

Source: company filings (standardised) and stockrow calculations.